Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug440 | BAY1211163 Dose 3 Wiki | 1.00 |
| drug442 | BAY1211163 Dose 5 Wiki | 1.00 |
| drug441 | BAY1211163 Dose 4 Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.09 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
COVID-19 is a respiratory disease due to a novel coronavirus (SARS-CoV-2) that causes substantial morbidity and mortality. To date, no treatment has been proved to be effective in COVID-19. Elderly patients and patients with comorbidities have the worse prognosis with a higher risk of hospitalization, ICU admission and death. The efficacy of an early outpatient treatment could be suggested but need to be confirmed. This confirmation is mandatory to improve prognosis of COVID-19 but also to avoid unsuspected deleterious effect of drugs already used in clinical practice but not based on evidence.
Description: Hospitalization at D20
Measure: Hospital admission Time: Day 20Description: This outcome corresponds to the number of patients who died on day 20.
Measure: Effect of treatment on Death at D20 Time: Day 20Description: This outcome corresponds to the number of patients who died on day 60.
Measure: Effect of treatment on Death at D60 Time: Day 60Description: This outcome corresponds to the number of patients who died due to COVID on day 20.
Measure: Effect of treatment on Death due to COVID at D20 Time: Day 20Description: This outcome corresponds to the number of patients who died due to COVID on day 60.
Measure: Effect of treatment on Death due to COVID at D60 Time: Day 60Description: This outcome corresponds to the number of participants who need ICU stay at day 20.
Measure: Effect of treatment on need for ICU stay at D20 Time: Day 20Description: This outcome corresponds to the number of participants who need ICU stay at day 60.
Measure: Effect of treatment on need for ICU stay at D60 Time: Day 60Description: This outcome evaluates the duration of patient's ICU stay at day 20.
Measure: Effect of treatment on duration of ICU stay at D20 Time: Day 20Description: This outcome evaluates the duration of patient's ICU stay at day 60.
Measure: Effect of treatment on duration of ICU stay at D60 Time: Day 60Description: This outcome corresponds to the number of participants who need mechanical ventilation at D20.
Measure: Effect of treatment on need of mechanical ventilation at D20 Time: Day 20Description: This outcome corresponds to the number of participants who need mechanical ventilation at D60.
Measure: Effect of treatment on need of mechanical ventilation at D60 Time: Day 60Description: This outcome corresponds to the duration of patient's mechanical ventilation at D20.
Measure: Effect of treatment on duration of mechanical ventilation at D20 Time: Day 20Description: This outcome corresponds to the duration of patient's mechanical ventilation at D60.
Measure: Effect of treatment on duration of mechanical ventilation at D60 Time: Day 60Description: This outcome evaluates the delay between inclusion and hospitalization at D20.
Measure: Effect of treatment on time to hospitalization at D20 Time: Day 20Description: This outcome evaluates the delay between inclusion and hospitalization at D60.
Measure: Effect of treatment on time to hospitalization at D60 Time: Day 60Description: This outcome evaluates the duration of patient's Hospital stay at D20.
Measure: Effect of treatment on Duration of Hospital stay et D20 Time: Day 20Description: This outcome evaluates the duration of patient's Hospital stay at D60.
Measure: Effect of treatment on Duration of Hospital stay et D60 Time: Day 60Description: This outcome evaluates the duration of symptoms at D20 after treatment.
Measure: Effect of treatment on Duration of symptoms at D20 Time: Day 20Description: This outcome evaluates the duration of symptoms at D60 after treatment.
Measure: Effect of treatment on Duration of symptoms at D60 Time: Day 60Description: This outcome measures the number of participants with treatment-related adverse events as assessed by CTCAE v4.0, at the end of study.
Measure: Incidence of Treatment-Emergent Adverse Events Time: Month 6Description: This outcome evaluates the chest radiological features on Chest HRCT, at 6 months, after treatment.
Measure: Effect of treatment on chest radiological features Time: Month 6Description: This outcome evaluates the Pulmonary function test at 6 month, after treatment.
Measure: Effect of treatment on respiratory capacity Time: Month 6Description: This ouctome eavaluates costs and consequences which will be presented for each stakeholder in a disaggregated way at the end of study.
Measure: Cost consequence analysis Time: Month 6Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports